09 September 2012 0 9K Report

As far as I know at the moment, only Sanger sequencing is reimbursed by health insurances of many countries. If the commissions in your region on reimbursement already worked on specific reimbursement for next-generation sequencing, what do they have as a definite concept on what kinds of rules and regulations apply to next-generation sequencing for the diagnostic of diseases?

Similar questions and discussions